

PRODUCT INFORMATION



Remogliflozin A

Item No. 14340

CAS Registry No.: 329045-45-6
Formal Name: 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl β-D-glucopyranoside

Synonym: GSK189074

MF: C₂₃H₃₄N₂O₇

FW: 450.5


Purity: ≥98%

UV/Vis.: λ_{max}: 229 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Remogliflozin A is supplied as a crystalline solid. A stock solution may be made by dissolving the remogliflozin A in the solvent of choice. Remogliflozin A is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of remogliflozin A in these solvents is approximately 30 mg/ml.

Remogliflozin A is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, remogliflozin A should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Remogliflozin A has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Remogliflozin A is a potent inhibitor of sodium-glucose transporter 2 (SGLT2; K_is = 12.4 and 26 nM for human and rat SGLT2, respectively).¹ It is selective for SGLT2 over SGLT1 (K_is = 4,520 and 997 nM for human and rat SGLT1, respectively). Following administration of a prodrug, remogliflozin etabonate, that is rapidly converted to remogliflozin A *in vivo*, rat urinary glucose excretion increases and plasma glucose and insulin concentrations decrease. Similar effects are observed following oral administration of remogliflozin etabonate to rats with diabetes induced by streptozotocin (Item No. 13104) and *db/db* mice with hyperinsulinemia and obesity.

Reference

1. Fujimori, Y., Katsuno, K., Nakashima, I., *et al.* Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. *J. Pharmacol. Exp. Ther.* **327**(1), 268-276 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/23/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM